O'Malley B P, Jennings P E, Cook N, Barnett D B, Rosenthal F D
Psychoneuroendocrinology. 1984;9(1):13-9. doi: 10.1016/0306-4530(84)90017-9.
We have studied the effects of ketanserin, a specific 5-HT2 antagonist, and zimelidine, a selective inhibitor of 5-HT re-uptake into central nervous system presynaptic terminals, upon basal and TRH stimulated serum TSH and prolactin levels in euthyroid individuals. Ten normal volunteers were studied (five male and five female), each receiving oral ketanserin and oral zimelidine during respective seven day periods, separated by an interval of at least two weeks. A standard TRH test (200 micrograms i.v.) was carried out before and after each period of drug administration, serum samples being obtained for TSH and prolactin estimation. We were unable to demonstrate any modification of basal or TRH-stimulated TSH and prolactin levels by the oral administration of either ketanserin or zimelidine, suggesting that 5-HT has no significant role in the physiological release of either TSH or prolactin.
我们研究了酮色林（一种特异性5-羟色胺2拮抗剂）和齐美利定（一种选择性抑制5-羟色胺再摄取进入中枢神经系统突触前终末的药物）对甲状腺功能正常个体基础及促甲状腺激素释放激素（TRH）刺激后的血清促甲状腺激素（TSH）和催乳素水平的影响。研究了10名正常志愿者（5名男性和5名女性），每人在各自为期7天的时间段内口服酮色林和口服齐美利定，两个时间段之间间隔至少两周。在每个给药期前后进行标准TRH试验（静脉注射200微克），采集血清样本用于TSH和催乳素测定。我们未能证明口服酮色林或齐美利定对基础或TRH刺激的TSH和催乳素水平有任何改变，这表明5-羟色胺在TSH或催乳素的生理释放中没有显著作用。
